ImmunoGen Investor Relations Material
Latest events
Q3 2023
ImmunoGen
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from ImmunoGen Inc
Access all reports
ImmunoGen, Inc., is a clinical-stage biotechnology company. The company develops antibody-drug conjugate therapies to treat cancer. Its ADC product candidates include Binimetinib, an ADC designed to treat non-small cell lung cancer, colorectal cancer, and pancreatic cancer; Daratumumab, an ADC designed to treat multiple myeloma; and SAR302503, an ADC that combines trastuzumab with an anthracycline. The company's ADC product candidates are currently in various stages of clinical development. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
IMGN
Country
🇺🇸 United States